Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VG161 + Nivolumab in Advanced Pancreatic Cancer
NCT05162118Phase 2Recruiting
- Sponsor
- Zhejiang University
- Start
- Mar 2022
- Primary completion
- Mar 2025
- Modality
- Gene Editing, Prophylactic Vaccines, Gene Silencing
- Countries
- 1
01
Overview
A Phase 2 trial of VG161 in pancreatic cancer (PC), sponsored by Zhejiang University. Started Mar 2022; status: recruiting.
02
Drugs
VG161
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT05162118.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05162118.